<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01236612</url>
  </required_header>
  <id_info>
    <org_study_id>EHMI9</org_study_id>
    <nct_id>NCT01236612</nct_id>
  </id_info>
  <brief_title>Experimental Human Malaria Infection After Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis</brief_title>
  <acronym>EHMI9</acronym>
  <official_title>Experimental Human Malaria Infection After Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Malaria is one of the major infectious diseases in the world with a tremendous impact on the&#xD;
      quality of life significantly contributing to the ongoing poverty in endemic countries. It&#xD;
      causes almost one million deaths per year, the majority of which are children under the age&#xD;
      of five. The malaria parasite enters the human body through the skin, by the bite of an&#xD;
      infected mosquito. Subsequently, it invades the liver and develops and multiplies inside the&#xD;
      hepatocytes. After a week, the hepatocytes burst open and the parasites are released in the&#xD;
      blood stream, causing the clinical phase of the disease.&#xD;
&#xD;
      As a unique opportunity to study malaria immunology and efficacy of immunisation strategies,&#xD;
      a protocol has been developed in the past to conduct experimental human malaria infections&#xD;
      (EHMIs). EHMIs generally involve small groups of malaria-naïve volunteers infected via the&#xD;
      bites of P. falciparum infected laboratory-reared Anopheline mosquitoes. Although potentially&#xD;
      serious or even lethal, Plasmodium falciparum (P.falciparum) malaria can be radically cured&#xD;
      at the earliest stages of blood infection where risks of complications are virtually absent.&#xD;
&#xD;
      The investigators have shown previously, that healthy human volunteers can be protected from&#xD;
      a malaria mosquito challenge by immunization with mosquito-bites under chloroquine&#xD;
      prophylaxis (CPS immunization). However, it is unknown whether this protection is based on&#xD;
      immunity directed towards the liver- or the blood stage of the disease. For future&#xD;
      development of vaccines and understanding of protective immunity to malaria, it is important&#xD;
      to investigate at which level protective immunity is generated by CPS immunization.&#xD;
      Therefore, we aim to investigate whether CPS immunization confers protection to a blood-stage&#xD;
      challenge.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of prepatent period as measured by microscopy</measure>
    <time_frame>21 days after challenge</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Parasitemia and kinetics of parasitemia as measured by PCR</measure>
    <time_frame>21 days after challenge</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of signs or symptoms in study groups</measure>
    <time_frame>21 days after challenge</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antibody production in groups 1, 2, 3 and 4</measure>
    <time_frame>393 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cellular immune response in groups 1, 2, 3 and 4</measure>
    <time_frame>393 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokine profile in groups 1, 2, 3 and 4</measure>
    <time_frame>393 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Plasmodium Falciparum Malaria</condition>
  <arm_group>
    <arm_group_label>Immunization + bloodstage challenge</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Immunization + mosquito challenge</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control - Bloodstage challenge</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control - Mosquito challenge</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chloroquine prophylaxis</intervention_name>
    <description>The chloroquine dose used will be 300mg for the first two days, followed by 300mg per week, for 13 weeks.</description>
    <arm_group_label>Immunization + bloodstage challenge</arm_group_label>
    <arm_group_label>Immunization + mosquito challenge</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Immunization</intervention_name>
    <description>Groups 1 and 2 will be immunized with 3 times 15 bites of Pf infected mosquitoes under chloroquine prophylaxis.</description>
    <arm_group_label>Immunization + bloodstage challenge</arm_group_label>
    <arm_group_label>Immunization + mosquito challenge</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Plasmodium falciparum Bloodstage challenge</intervention_name>
    <description>Groups 1 and 3 will be challenged by intravenous administration of Plasmodium falciparum infected erythrocytes.</description>
    <arm_group_label>Control - Bloodstage challenge</arm_group_label>
    <arm_group_label>Immunization + bloodstage challenge</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Plasmodium falciparum mosquito challenge</intervention_name>
    <description>Groups 2 and 4 will be challenged by the bites of 5 Plasmodium falciparum infected mosquitoes.</description>
    <arm_group_label>Control - Mosquito challenge</arm_group_label>
    <arm_group_label>Immunization + mosquito challenge</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Malarone treatment</intervention_name>
    <description>When thick smear positive, of ar day 21 after challenge, all volunteers will be treated with malarone.</description>
    <arm_group_label>Control - Bloodstage challenge</arm_group_label>
    <arm_group_label>Control - Mosquito challenge</arm_group_label>
    <arm_group_label>Immunization + bloodstage challenge</arm_group_label>
    <arm_group_label>Immunization + mosquito challenge</arm_group_label>
    <other_name>atovaquon/proguanil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt; 18 and &lt; 35 years healthy volunteers (males or females)&#xD;
&#xD;
          2. Good health based on history and clinical examination&#xD;
&#xD;
          3. Negative pregnancy test&#xD;
&#xD;
          4. Use of adequate contraception for females&#xD;
&#xD;
          5. All volunteers must sign the informed consent form demonstrating their understanding&#xD;
             of the meaning and procedures of the study&#xD;
&#xD;
          6. Volunteer agrees to inform the general practitioner and agrees to sign a request to&#xD;
             release medical information concerning contra-indications for participation in the&#xD;
             study&#xD;
&#xD;
          7. Willingness to undergo a Pf mosquito or blood stage challenge&#xD;
&#xD;
          8. For volunteers not living in Nijmegen: agreement to stay in a hotel room close to the&#xD;
             trial center during a part of the study (for groups 1 and 3 from challenge day till 3&#xD;
             days after treatment, for groups 2 and 4 from 5 days after challenge till 3 days after&#xD;
             treatment)&#xD;
&#xD;
          9. Reachable (24/7) by mobile phone during the whole study period&#xD;
&#xD;
         10. Living with a third party that could contact the clinicians in case of alteration of&#xD;
             consciousness or agreement to stay in a hotel room close to the trial center during a&#xD;
             part of the study (for groups 1 and 3 from challenge day till 3 days after treatment,&#xD;
             for groups 2 and 4 from 5 days after challenge till 3 days after treatment)&#xD;
&#xD;
         11. Available to attend all study visits&#xD;
&#xD;
         12. Agreement to refrain from blood donation to Sanquin or for other purposes, during the&#xD;
             study period until 393&#xD;
&#xD;
         13. Willingness to undergo HIV, hepatitis B and hepatitis C tests&#xD;
&#xD;
         14. Negative urine toxicology screening test at screening visit and day before challenge&#xD;
&#xD;
         15. Willingness to take a prophylactic regime of chloroquine and curative regimen of&#xD;
             Malarone®&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of malaria&#xD;
&#xD;
          2. Plans to travel to malaria endemic areas during the study period&#xD;
&#xD;
          3. Plans to travel outside of the Netherlands during the challenge period&#xD;
&#xD;
          4. Previous participation in any malaria vaccine study and/or positive serology for Pf&#xD;
&#xD;
          5. Symptoms, physical signs and laboratory values suggestive of systemic disorders&#xD;
             including renal, hepatic, cardiovascular, pulmonary, skin, immunodeficiency,&#xD;
             psychiatric, and other conditions which could interfere with the interpretation of the&#xD;
             study results or compromise the health of the volunteers&#xD;
&#xD;
          6. History of diabetes mellitus or cancer (except basal cell carcinoma of the skin)&#xD;
&#xD;
          7. History of arrhythmias or prolonged QT-interval&#xD;
&#xD;
          8. Positive family history in 1st and 2nd degree relatives for cardiac disease &lt; 50 years&#xD;
             old&#xD;
&#xD;
          9. An estimated, ten year risk of fatal cardiovascular disease of ≥5%, as estimated by&#xD;
             the Systematic Coronary Risk Evaluation (SCORE) system&#xD;
&#xD;
         10. Clinically significant abnormalities in electrocardiogram (ECG) at screening&#xD;
&#xD;
         11. Body Mass Index (BMI) below 18 or above 30 kg/m2&#xD;
&#xD;
         12. Any clinically significant deviation from the normal range in biochemistry or&#xD;
             hematology blood tests or in urine analysis&#xD;
&#xD;
         13. Positive HIV, HBV or HCV tests&#xD;
&#xD;
         14. Participation in any other clinical study within 30 days prior to the onset of the&#xD;
             study&#xD;
&#xD;
         15. Enrollment in any other clinical study during the study period&#xD;
&#xD;
         16. Pregnant or lactating women&#xD;
&#xD;
         17. Volunteers unable to give written informed consent&#xD;
&#xD;
         18. Volunteers unable to be closely followed for social, geographic or psychological&#xD;
             reasons&#xD;
&#xD;
         19. Previous history of drug or alcohol abuse interfering with normal social function&#xD;
             during a period of one year prior to enrolment in the study&#xD;
&#xD;
         20. A history of psychiatric disease&#xD;
&#xD;
         21. Known hypersensitivity to anti-malaria drugs&#xD;
&#xD;
         22. The use of chronic immunosuppressive drugs, antibiotics, or other immune modifying&#xD;
             drugs within three months of study onset (inhaled and topical corticosteroids are&#xD;
             allowed) and during the study period&#xD;
&#xD;
         23. Contra-indications to Malarone® or chloroquine including treatment taken by the&#xD;
             volunteer that interferes with Malarone® or chloroquine&#xD;
&#xD;
         24. Any confirmed or suspected immunosuppressive or immunodeficient condition, including&#xD;
             asplenia&#xD;
&#xD;
         25. Co-workers of the departments of Medical Microbiology or Internal Medicine of the&#xD;
             RUNMC&#xD;
&#xD;
         26. A history of sickle cell anemia, sickle cell trait, thalassemia, thalassemia trait or&#xD;
             G6PD deficiency&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert W Sauerwein, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radboud University Nijmegen Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Roestenberg M, McCall M, Hopman J, Wiersma J, Luty AJ, van Gemert GJ, van de Vegte-Bolmer M, van Schaijk B, Teelen K, Arens T, Spaarman L, de Mast Q, Roeffen W, Snounou G, Rénia L, van der Ven A, Hermsen CC, Sauerwein R. Protection against a malaria challenge by sporozoite inoculation. N Engl J Med. 2009 Jul 30;361(5):468-77. doi: 10.1056/NEJMoa0805832.</citation>
    <PMID>19641203</PMID>
  </reference>
  <results_reference>
    <citation>Bijker EM, Bastiaens GJ, Teirlinck AC, van Gemert GJ, Graumans W, van de Vegte-Bolmer M, Siebelink-Stoter R, Arens T, Teelen K, Nahrendorf W, Remarque EJ, Roeffen W, Jansens A, Zimmerman D, Vos M, van Schaijk BC, Wiersma J, van der Ven AJ, de Mast Q, van Lieshout L, Verweij JJ, Hermsen CC, Scholzen A, Sauerwein RW. Protection against malaria after immunization by chloroquine prophylaxis and sporozoites is mediated by preerythrocytic immunity. Proc Natl Acad Sci U S A. 2013 May 7;110(19):7862-7. doi: 10.1073/pnas.1220360110. Epub 2013 Apr 18.</citation>
    <PMID>23599283</PMID>
  </results_reference>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>November 4, 2010</study_first_submitted>
  <study_first_submitted_qc>November 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2010</study_first_posted>
  <last_update_submitted>January 20, 2014</last_update_submitted>
  <last_update_submitted_qc>January 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Plasmodium</keyword>
  <keyword>falciparum</keyword>
  <keyword>malaria</keyword>
  <keyword>chloroquine</keyword>
  <keyword>immunity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Falciparum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chloroquine</mesh_term>
    <mesh_term>Proguanil</mesh_term>
    <mesh_term>Atovaquone, proguanil drug combination</mesh_term>
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

